Core Viewpoint - A class action lawsuit has been filed against Red Cat Holdings, Inc. for allegedly misleading investors regarding its production capacity and the value of its contracts, particularly the U.S. Army's Short Range Reconnaissance Program [1][2][3] Allegations - The complaint states that Red Cat Holdings overstated the production capacity of its Salt Lake City Facility and the overall value of the SRR Contract [2] - Kerrisdale Capital's report claims the SRR Contract is valued between $20 million and $25 million, contrary to Red Cat's representations [3] - Following the report, Red Cat's stock price dropped by $2.35 per share, or 21.54%, closing at $8.56 on January 17, 2025 [3] Class Action Participation - Shareholders interested in serving as lead plaintiffs have until July 22, 2025, to apply for this status [4] - Participation in the class action is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4] Company Background - Robbins LLP is noted for its focus on shareholder rights litigation, aiming to help shareholders recover losses and improve corporate governance [5]

Group 1 - A class action has been filed against Petco Health and Wellness Company, Inc. for misleading investors regarding its business prospects during the period from January 14, 2021, to June 5, 2025 [1][2] - Allegations include that Petco's pandemic-related growth was unsustainable and that the company overstated its ability to deliver sustainable, profitable growth [2] - The complaint highlights that the true scope of issues affecting Petco's business model and sales metrics was downplayed by the defendants [2] Group 2 - Shareholders may participate in the class action and can contact Robbins LLP if they wish to serve as lead plaintiff [3] - The representation in the class action is on a contingency fee basis, meaning shareholders pay no fees or expenses [4] - Robbins LLP has been dedicated to helping shareholders recover losses and improve corporate governance since 2002 [4]

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. for allegedly misleading investors regarding the safety of its gene therapy drug, ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [1][2]. Allegations - The lawsuit claims that Sarepta failed to disclose significant safety risks associated with ELEVIDYS, including the inability of trial protocols to detect severe side effects and the potential for adverse events to halt recruitment and dosing in clinical trials [2]. - Specific allegations include that the severity of adverse events would attract regulatory scrutiny and increase risks surrounding the therapy's approvals [2]. Stock Price Impact - Following a safety update on March 18, 2025, which reported a patient death after ELEVIDYS treatment, Sarepta's stock price dropped by $27.81, or 27.44%, closing at $73.54 [3]. - On June 15, 2025, after disclosing a second patient death due to acute liver failure and announcing a suspension of shipments for non-ambulatory patients, the stock fell by $15.24, or 42.12%, closing at $20.91 [3]. - The FDA's investigation announcement on June 24, 2025, regarding the risk of acute liver failure led to an additional stock price decline of $1.52, or 8.01%, closing at $17.46 [4]. Class Action Participation - Shareholders interested in participating as lead plaintiffs in the class action must file a motion by August 25, 2025, although participation is not required to be eligible for recovery [5].

The administration today formally accused Harvard of violating civil rights laws by not doing enough to fight anti-semitism. We know that the president has tal talked to us before about um Harvard potentially having a deal with administration in the coming days. Do you have an updated timeline for that.How's the negotiations going. And is more pressure needed for Harvard to take fighting anti-semitism seriously. Well, there was um quite a direct letter that was sent to Harvard this morning as you know.um th ...

Hello everyone. My name is uh Muslim Axam Haja. I am from Tashkin and um I'm from private school.I came here to stand there and talk about feminism itself. My topic is why feminism still matters in the 21st century. So I will start uh I will try to explain and help other people to understand it.So I like to start my speech with um with the situation I recently faced that I don't understand uh where so many um misinformation came from about feminism. Like a lot of people think that feminism is about unshaved ...

Well, Pride Month wrapped up this weekend with a big march right here in New York City yesterday. It comes as many in the LGBTQ plus community say their rights are at risk from coast to coast. NBC News correspondent Maya Eagland has more.Pride weekend in New York City wrapping up the month-long celebration of LGBTQ plus rights amid a year of setbacks for the community. It's needed cuz we need to show people that we're here. We're not going away.Across the country, festivities drawing crowds in San Francisco ...

The US Supreme Court ordered reconsideration of rulings backing transgender rights in clashes over health care and birth certificates https://t.co/zZoDgnhnn6 ...

The US Supreme Court refused to consider arguments that Los Angeles violated the constitutional rights of landlords by barring evictions during the Covid-19 pandemic https://t.co/SiRzF87Np5 ...

The US Supreme Court will consider whether activist investors can use an 85-year-old law to challenge corporate moves bolstering controlling shareholders https://t.co/nzLLwChlye ...

The US government told Harvard it violated federal civil-rights law in its treatment of Jewish and Israeli students https://t.co/RrAhnh2zUd ...